Trial Profile
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed By Standard Chemoradiation In HPV-Negative or High-risk HPV-Positive Locally Advanced Stage III/IVa/IVb HNSCC
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary) ; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Aug 2018 Status changed to discontinue.
- 12 Oct 2016 Planned End Date changed from 1 Jan 2017 to 1 Jan 2019.
- 15 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.